Advanced Practice

Triple M Syndrome: Implications for Hematology-Oncology Advanced Practice Providers

Lisa A. Kottschade

Casey Fazer-Posorske

Anna J. Schwecke

immune checkpoint inhibitor, myositis, myocarditis, myasthenia gravis
CJON 2023, 27(5), 463-467. DOI: 10.1188/23.CJON.463-467

During the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the landscape of cancer treatment. ICI-related side effects occur via direct overactivation of the immune system, and patients can experience symptoms akin to autoimmune disease. These symptoms can range in severity from mild to severe and can be fatal. Advanced practice providers require a heightened awareness of the wide range of immune-related adverse events that can occur with ICI therapy.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.